MCPHS / Sanofi – US Medical - MSL / (Rare Blood Disorders) - Rare Diseases, Post PharmD Fellow
MCPHS/Sanofi
Application
Details
Posted: 10-Oct-24
Location: Cambridge, Massachusetts
Type: Fellowship
Salary: Open
Job Setting:
Pharmaceutical Science/Industry
Salary Details:
Additional Salary Information: Fellows will receive a competitive stipend and benefit package, including comprehensive health insurance.
Required Education:
PharmD
Internal Number: 1111
About
Sanofi's Rare Blood Disorder team supports HCPs and Patients across Hemophilia, aTTP, and Immune Thrombocytopenia.
Program Goals
The US Rare Blood Disorders (RBD) Medical Fellowship program is designed to give you a well-rounded experience of US Medical Affairs by fully integrating as a member of our RBD Medical team. The core focus is gaining experience and exposure to the various roles in US Medical (Medical Director, Operations, Field Roles) and develop necessary skills and behaviors to be a successful Medical Affairs Professional (in-house and field). As RBD prepares for key product launches in 2025, this position will gain unique experience with products new to market.
The fellowship will be divided into 4 parts- 1. Medical Director Responsibilities, 2. Medical Operations, 3. Field Medical, 4. Flex
Primary Objectives
Under the mentorship of a US Medical Director, gain understanding in what the role of the Medical Director encompasses- strategic planning, subject matter expertise, cross-functional partnership, execution of strategy (ad boards, training, content development, etc.)
Working with the Operations Director (in-house and field) to gain understanding of skills needed to ensure the US Medical organization operates effectively while driving initiatives forward- budget, tracking of activities, metrics, field system optimization and congress planning
Working with a MSL mentor in the field to gain skills in effective communication of scientific data, application of medical strategy, and engagement with external stakeholders in 1:1 and group settings.
To be considered for an interview, please complete a fellowship application on the MCPHS SMApply application portal. Visit https://mcphs.smapply.io/
Please DO NOT request an interview within PPS. Our recruitment teams will contact qualified candidates via email to schedule interviews.
The MCPHS application portal will open up on Monday, October 7, 2024. Applicants must upload the following application materials to the online portal by Monday, November 4, 2024:
Letter of intent (addressed to the company specific program director/lead; found in each company brochure)
Curriculum vitae
Unofficial college transcript
Contact information for three references. References will receive an electronic recommendation form to complete separately.
Incomplete applications WILL NOT be reviewed. Interviews CANNOT be scheduled until these materials have been submitted. Please keep in mind that this is a competitive process and applicants are encouraged to complete their applications as soon as possible.
Recommendations
Three recommendation evaluation forms must be submitted no later than November 20, 2024 via the online portal. This is NOT a letter of recommendation but an online form that the reference will need to complete.
Application Review and Interview Timeline
Following a review of submitted applications, pre-screens and preliminary interviews will begin in October. Additional interviews, including final rounds will take place in December during ASHP. Candidates will be notified if selected for an interview. The process is rigorous and competitive; therefore, candidates should submit their applications well in advance of posted deadlines as priority will be given to those who apply early.
ASHP Midyear & Onsite Interviews
The fellowship program will be conducting in-person interviews at the ASHP Midyear Clinical Meeting in New Orleans, LA. Attendance is strongly encouraged, but not required. Candidates attending in-person will not be able to interview without registering for both ASHP and PPS. Please refer to the ASHP & PPS website for registration details.
Top candidates may be invited for interviews at the sponsoring company’s location.
AIFA First Offer Date
The choice of a Post-Doctoral Fellowship is an important decision. MCPHS, in conjunction with the Alliance of Industry Fellowship Associates (AIFA), has aligned to extend offers for Fellowships no earlier than December 16, 2024. We believe this is a positive reflection of the cultures our Programs offer, and that culture is a critical consideration in choice of Fellowship. We hope that other academic and non-academic Fellowship Programs will NOT pressure candidates to accept offers prior to this aligned offer date.
We see this respect for candidate choice as a common aspect of each of our Program's cultures. We hope that other academic and non-academic Fellowship Programs will respect this timeline.
Onboarding
Final candidates will be required to go through additional screening / onboarding as required by MCPHS.
Eligibility
The MCPHS Biopharmaceutical Industry fellows will be selected on a nationally competitive basis.
Applicants must have a Doctor of Pharmacy degree from an ACPE accredited college of pharmacy at the commencement of the program.
Candidates must have strong written and verbal communication skills and a strong interest in pursuing a career within the biopharmaceutical industry.
All candidates must have authorization to work in the United States throughout the duration of the one or two year fellowship. No visa sponsorship will be provided (i.e., TN, H-1B, STEM OPT, etc.).
Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Sanofi’s global specialty care business unit focuses on rare diseases, rare blood disorders, neurology, immunology, and oncology. Its approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Our cutting-edge science and manufacturing, fueled by data and digital technologies, have the potential to transform the practice of medicine for millions of people around the world.